Partnering with a CDMO - Past the Service Offering

1:45 PM - 2:05 PM (PDT), Tuesday, June 14, 2022

Progress in the gene and cell therapy, coupled with positive outcomes of many clinical trials based on advanced therapies heightened the demand for contract manufacturing and development organizations (CDMOs). It is imperial to consider a partnership with these entities and not a fee-for-service transaction. Clients naturally focus on the available capacity when selecting a CDMO partner. Other crucial qualities that tend to be overlooked during CDMO search such as the technical capability, quality systems and regulatory track records, should be pivotal considerations when selecting a long term CDMO partner.  An effective CDMO search should result in a partner that has available capacity, state-of-the art technologies, skilled resources, proven quality systems, significant GMP manufacturing experience, flexible business approaches and secure financial position to truly support their clients in producing life-saving advanced gene and cell therapies.

Speaker
photo
Vice President, PD, Viral Vector Technologies
Avid Bioservices, Inc.